Corcept Therapeutics Incorporated is a biotechnology business based in the US. Corcept Therapeutics Incorporated shares (CORT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $70.23 – a decrease of 5.02% over the previous week. Corcept Therapeutics Incorporated employs 500 staff and has a trailing 12-month revenue of around $685.4 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $70.23 |
|---|---|
| 52-week range | $26.87 - $117.33 |
| 50-day moving average | $66.26 |
| 200-day moving average | $53.86 |
| Wall St. target price | $138.25 |
| PE ratio | 61.0696 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.15 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $70.23 from 2025-05-09
| 1 week (2025-05-02) | -3.49% |
|---|---|
| 1 month (2025-04-11) | 2.35% |
| 3 months (2025-02-13) | -4.59% |
| 6 months (2024-11-13) | 24.41% |
| 1 year (2024-05-13) | 155.10% |
|---|---|
| 2 years (2023-05-11) | 193.73% |
| 3 years (2022-05-12) | 277.18% |
| 5 years (2020-05-11) | 411.51% |
Valuing Corcept Therapeutics Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Corcept Therapeutics Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Corcept Therapeutics Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 61x. In other words, Corcept Therapeutics Incorporated shares trade at around 61x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Corcept Therapeutics Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Corcept Therapeutics Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Corcept Therapeutics Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $111.3 million.
The EBITDA is a measure of a Corcept Therapeutics Incorporated's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $685.4 million |
|---|---|
| Operating margin TTM | 2.17% |
| Gross profit TTM | $674.2 million |
| Return on assets TTM | 9.18% |
| Return on equity TTM | 21.77% |
| Profit margin | 19.55% |
| Book value | $6.45 |
| Market Capitalization | $7.4 billion |
TTM: trailing 12 months
We're not expecting Corcept Therapeutics Incorporated to pay a dividend over the next 12 months.
Over the last 12 months, Corcept Therapeutics Incorporated's shares have ranged in value from as little as $26.87 up to $117.33. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corcept Therapeutics Incorporated's is 0.213. This would suggest that Corcept Therapeutics Incorporated's shares are less volatile than average (for this exchange).
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California. .
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.